MedTrace Logo

Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations

NCT07581379 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1826

Last updated 2026-05-12

No results posted yet for this study

Summary

This observational study evaluates the effectiveness of computed tomography (CT) imaging surveillance after curative-intent treatment for stage I-IIIA non-small cell lung cancer (NSCLC) in a diverse U.S. population.

The main questions are:

How do CT surveillance use and adherence vary by race, ethnicity, and socioeconomic status?

Does semi-annual CT surveillance improve outcomes compared with annual surveillance?

Adults ages 20-90 with stage I-IIIA NSCLC treated between 2012 and 2026 will be identified using OneFlorida+ electronic health records, tumor registry data, claims, and clinical notes. Patients will be followed for up to five years after curative-intent therapy to evaluate surveillance patterns, recurrence, second primary lung cancers, complications, and survival.

Conditions

  • Lung Neoplasms
  • Second Primary Lung Cancer (SPLC)
  • Non-Small Cell Lung Cancer (NSCLC), Stage I-IIIA
  • Lung Cancer (Diagnosis)

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Kaiser Permanente

    collaborator OTHER

  • University of Florida

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07581379 on ClinicalTrials.gov